Glenmark Life Sciences is a leading pharmaceutical company that specializes in the manufacturing of active pharmaceutical ingredients (APIs) and intermediates. The company is planning to undertake a significant expansion project in Darfal (Bibi), Solapur, Maharashtra, India. The proposed project involves expanding the existing API and intermediates manufacturing unit to increase its production capacity to 1282.70 Tonnes Per Annum (TPA).The estimated cost of the expansion project is Rs. 5500 million, indicating a considerable investment in the expansion of the manufacturing operations. The project cost includes the expenses incurred for the procurement of machinery, equipment, raw materials, hiring and training of employees, and other related expenses. As of February 2023, the project has been submitted to the Ministry of Environment & Clearance for final environmental clearance and is currently under examination. The company has completed the initial planning phase and is prepared to commence the construction of the new manufacturing unit upon receiving the necessary approvals.
For more details of this project : Rs.5500 Million API & Intermediates Mfg. Unit Expansion Project in Solapur, Maharashtra
